Intended for US Healthcare Professionals only.
FOR HEALTHCARE PROFESSIONALS
Resources
Explore helpful resources for you and your patients.
Use these links to connect with the resources below.
BAVARIAN NORDIC
Below are resources provided by Bavarian Nordic you can view and download for use.
JYNNEOS Billing and Coding Guide JYNNEOS HCP FlashcardThese organizations are not affiliated with Bavarian Nordic and resources are provided as a courtesy. The respective organizations are responsible for content and accuracy of their websites. Inclusion of these resources does not represent an endorsement of Bavarian Nordic products by the organizations.
Centers for Disease Control and Prevention (CDC)
The CDC provides further information on mpox including guides for testing and prevention tips for patients.
Visit each resource below.
Mpox Information for Healthcare Professionals Guidelines for Collecting and Handling Specimens for Mpox Testing Clinical Recognition for Mpox Clinical Quick Reference for Mpox Mpox Prevention
World Health Organization (WHO)
Let your patients know that they can visit the WHO website to learn about mpox.
Visit the Mpox website
National STD Curriculum (NSTDC)
The University of Washington Infectious Diseases Education and Assessment Program (IDEA) provides an educational guide for healthcare professionals involved in the care of persons with mpox.
Visit the Mpox Clinical GuideIndication and Usage
JYNNEOS® is approved for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.
Important Safety Information
Appropriate medical treatment must be available to manage possible anaphylactic reactions following administration of JYNNEOS. Anyone who has who experienced a severe allergic reaction following a previous dose of JYNNEOS or following exposure to any component of JYNNEOS may be at increased risk for severe allergic reactions.
Syncope (fainting) has been reported following vaccination with JYNNEOS. Procedures should be in place to avoid injury from fainting.
Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to JYNNEOS.
Vaccination with JYNNEOS may not protect all recipients.
In smallpox vaccine-naïve healthy adults, the most common (>10%) solicited injection site reactions were pain (84.9%), redness (60.8%), swelling (51.6%), induration (firmness at the injection site) (45.4%), and itching (43.1%); the most common solicited systemic adverse reactions were muscle pain (42.8%), headache (34.8%), fatigue (30.4%), nausea (17.3%) and chills (10.4%).
In healthy adults previously vaccinated with a smallpox vaccine, the most common (>10%) solicited injection site reactions were redness (80.9%), pain (79.5%), induration (70.4%), swelling (67.2%), and itching (32.0%); the most common solicited systemic adverse reactions were fatigue (33.5%), headache (27.6%), and muscle pain (21.5%).
The frequencies of solicited local and systemic adverse reactions among adults with HIV infection and adults with atopic dermatitis were generally similar to those observed in healthy adults.
Across all studies, a causal relationship to JYNNEOS could not be excluded for 5 SAEs, all non-fatal, which included Crohn’s disease, sarcoidosis, extraocular muscle paresis, throat tightness, and hemolytic anemia.
Among the cardiac AESIs reported, 6 cases (<0.1%) were considered to be causally related to JYNNEOS vaccination and included tachycardia, electrocardiogram T wave inversion, electrocardiogram abnormal, electrocardiogram ST segment elevation, electrocardiogram T wave abnormal, and palpitations. None of the cardiac AESIs considered causally related to study vaccination were considered serious.
JYNNEOS is for subcutaneous injection only.
To report SUSPECTED ADVERSE REACTIONS, contact Bavarian Nordic at 1-833-365-9596 or the US Department of Health and Human Services by either visiting www.vaers.hhs.gov/reportevent.html or calling 1-800-822-7967.